07/21/2026
New research is offering hope for patients battling mesothelioma.
An experimental drug called RSO-021 has shown encouraging results in an early clinical trial, helping control disease progression in many patients while demonstrating a favorable safety profile. While additional research is still needed, these findings represent an exciting step toward developing more effective treatments for this aggressive asbestos-related cancer.
Read more about this promising breakthrough on our blog:
A new experimental drug, RSO-021, showed promising results in a Phase I mesothelioma trial, offering hope for improved treatment and longer survival.